Form 8-K PLIANT THERAPEUTICS, For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)
August 8, 2024 9:30 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $32.00 price target on Pliant Therapeutics (NASDAQ: PLRX).
The analyst comments "We remain Buy Rated on PLRX following their 2Q24 update. The Ph2/3 BEACON-IPF trial remains the key driver for shares over the next 12-18... More



